Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (July 24th Preview)
-
Obesity drug progress toward BLA
Eli Lilly advanced its “triple-G” obesity program as additional Phase 3 results cleared the path toward a U.S. regulatory filing for retatrutide. The company reported top-line readouts across two obesity trials that also enrolled patients with type 2 diabetes and cardiovascular complications. In the obesity-and-diabetes study (Triumph-2) and the severe obesity-and-cardiovascular-disease study (Triumph-3), retatrutide demonstrated sustained weight-loss endpoints at multiple dose levels over 80 weeks. Lilly is now looking to submit a BLA early next year, positioning the asset for potential competition against established incretin-based therapies. Analysts framed the dataset as reinforcing retatrutide’s differentiation within the incretin portfolio, while also noting that the degree of cardiovascular risk reduction remains a key open question ahead of review.
-
FDA advisory panel backs broader access to unapproved peptides
An FDA advisory panel voted narrowly in favor of expanding compounding for certain unapproved peptides, setting up a consequential next step in a high-profile regulatory fight. The panel supported allowing compounding pharmacies to manufacture epitalon while voting against manufacturing emideltide, in deliberations that followed similar recommendations for additional peptides earlier. The vote is non-binding, but it signals how far the Pharmacy Compounding Advisory Committee’s recommendations could push the FDA toward lifting or relaxing current restrictions. The discussion also reflects broader scrutiny of whether limited evidence for safety and effectiveness should be expanded through compounding channels. For the biotech and pharma sector, the outcome could reshape incentives and risk tolerance around products that have not cleared standard FDA approval pathways.
-
CRISPR biotech raises capital in hot IPO window
Scribe Therapeutics kicked off trading after pricing an upsized initial public offering focused on CRISPR-based therapies for cardiovascular and metabolic diseases. The company raised about $129 million from an offering of 8.6 million shares at $15 each, beginning Nasdaq trading under ticker SCTX. The IPO pricing at the top end of its range and the sharp first-day pop underscored renewed investor appetite for gene-editing platforms. Scribe’s funding is intended to support early clinical progress and pipeline development, with the company emphasizing in vivo gene editing as it expands beyond rare-disease-only narratives. The transaction adds to a streak of strong public-market openings for gene and cell therapy companies, where investors are paying for platform credibility and near-term readouts.
-
CAR-T toxicity genomics in Yescarta trials
Researchers analyzing patient data from Kite’s Yescarta CAR-T trials identified genetic signatures associated with toxicity risk. In a study published in Science Immunology, investigators led by Massachusetts General Hospital oncologist Mark Leick analyzed data from the Zuma-1 and Zuma-7 studies of axi-cel. The work highlighted STXBP2 as a gene of interest, with mutations in Zuma-1 patients linked to treatment toxicity patterns. The researchers did not observe the same relationship in Zuma-7, which they attribute to differences in disease severity across the cohorts. The findings support further engineering work aimed at reducing CAR-T adverse events and improving therapy safety variability at the design stage using patient or tumor-linked risk biology.
-
EU regulator setback for Zevra’s NPC therapy
Zevra Therapeutics received a negative CHMP opinion in the EU for arimoclomol in Niemann-Pick disease type C, despite prior U.S. approval. The EMA’s Committee for Medicinal Products for Human Use concluded that efficacy was not sufficiently proven for the new management application. Zevra said it will request a re-examination, and it continues to support eligible patients through an EU expanded access program that has been generating real-world evidence for the drug. The negative opinion is a key commercial and regulatory headwind for the company, given that the therapy is positioned as a disease-modifying complement to miglustat.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.